Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Investor Presentation (November 2020)
35 slides from Jubilant Pharmova's investor presentation, November 2020
Slide 1: Jubilant Life Sciences Limited Investor Presentation November 2020
Jubilant Life Sciences Limited Investor Presentation November 2020
Slide 2: Disclaimer
Disclaimer Important Disclaimer This presentation (the “Presentation”, or the “document”) has been prepared by Jubilant Life Sciences Limited (the “Company”) for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for
Slide 3: Jubilant Life Sciences Overview
Jubilant Life Sciences Overview Pharmaceuticals Life Science Ingredients DDDS1 Specialty Pharmaceuticals Specialty Intermediates Drug Discovery & Radiopharma Advanced Intermediates Development Allergy Therapy Products Specialty Ingredients Solutions (Jubilant Biosys) CDMO Nutritional Product
Slide 4: High-Quality, World-Class, Low Cost Manufacturing Footprint
5 High-Quality, World-Class, Low Cost Manufacturing Footprint Spokane, Washington, USA Roorkee, Uttarakhand Contract manufacturing of Sterile Generics manufacturing injectable and Allergy therapy Gajraula, Uttar Pradesh Largest integrated facility of Specialty Intermediates and Samlaya, Gujara
Slide 5: Experienced Management team with high standards of corporate governance
Experienced Management team with high standards of corporate 6 governance Shyam S Bhartia Hari S Bhartia Chairman Co-Chairman & Managing Director 39 industry years in pharma, specialty 33 industry years in pharma, specialty chemicals, foods, oil and gas, aerospace and IT chemicals, foods, oil and ga
Slide 6: Pharmaceuticals Segment
f) we - . i a wW jupiaAnt Pharmaceuticals Segment LIFESCIENCES
Slide 7: Evolution of Jubilant Pharma
Evolution of Jubilant Pharma Revenue Contribution JLL acquired Acquired a majority stake Acquired Draxis SGX-listed Completed JPL entered FY20 API business – in Cadista Holdings Inc. Pharma Inc. in high yield acquisition of into a US$803m Nanjangud, (generics pharmaceutical Canada bond Triad’s strat
Slide 8: Radiopharmaceuticals Business
Radiopharmaceuticals Business Radiopharmaceuticals Industry in North America is US$2.7bn in 2019 Market Size of Industry in North America Expected to more than double by 2029 led by PET imaging and theragnostic applications 3.5 3.0 3.2 Industry 2.7 2.9 Oncology and cardiology diagnosis account
Slide 9: Radiopharmaceuticals Business – Key Products
Radiopharmaceuticals Business – Key Products RUBY-FILL® (Rubidium Kit for the Preparation HICON® Sodium Iodide Rb-82 Generator) and of Technetium Tc 99m I-131 Solution USP Elution System Albumin Aggregated Injection (MAA) The RUBY-FILL® Rubidium Rb 82 Used as an adjunct in the evaluation of HI
Slide 10: Radiopharmacy Business
Radiopharmacy Business # 2 commercial radiopharmacy network(1) in the US, operated under the Jubilant Radiopharmacy brand Facilities include three cyclotrons Multi-year agreements with GPOs in place 49 radiopharmacies spread across 22 states ~750 employees c.2.8 mn+ doses delivered annually c.
Slide 11: Allergy Therapy Business
Allergy Therapy Business Allergen Immunotherapy (AIT) Market Size Global AIT market stands at US$1.6bn and is expected to grow at CAGR of 8.9% to reach 2.8 2.6 US$2.8bn by 2022 2.3 0.5 2.0 2.1 1.8 0.4 1.6 1.7 0.4 Major growth drivers include the increased prevalence of allergic diseases, reduced
Slide 12: Allergy Therapy Business – Key Products
Allergy Therapy Business – Key Products ComforTen Skin Test System Allergenic extract Venom products The only self-loading, surgical Jubilant has a broad & diverse More than 16 million Americans are at risk for a steel skin test system on the portfolio across all the major allergen potentially
Slide 13: Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products
Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products Global Pharmaceutical CMO Industry Size 125 134 Injectable market stands at US$5.4bn and is expected to outpace the industry (ex API) by growing at a 109 117 5 5 7 100 5 7 12 79 85 92 4 5 6 6 12 11 CAGR of 4.7% between
Slide 14: API Business
API Business Global Market Size : Synthetic API1 149 123 131 129 Global Synthetic API market is US$115bn in 2018 and is expected to grow at a 115 Industry 53 46 62 CAGR of 6.7% from 2018 to 2022F to reach US$149bn(1) 51 (US$bn) 48 Overview 53% of outsourced API market is generics(1) 67 72 78 83
Slide 15: Solid Dosage Formulations Business
Solid Dosage Formulations Business Global Generics Pharmaceuticals Industry Size by Unbranded Generic US Patent Expiry for Small Molecules Sales(1)(3) Global generics pharmaceutical industry stands at US$111bn and is expected to grow at CAGR of 5.2% to reach US$136bn US$ 72.5 bn 136 by 2023 117 12
Slide 16: Life Science Ingredients Segment
Life Science Ingredients Segment
Slide 17: Specialty Intermediates
Specialty Intermediates Global Market Size ($ Bn) : Speciality Chemicals Global specialty chemicals market is USD 240 billion in 2019 and is expected to grow at 5.4% to reach USD 267 billion in 2022. Industry New Opportunities in Pharma and Agro chemicals are emerging Overview post Covid pandemi
Slide 18: Nutritional Products
Nutritional Products Global nutrition market is USD 570 billion in 2019 , largely dominated by feed business and food ingredients. Industry Animal Feed contributes ~80% of total Nutrition market Overview Animal Feed Additive market in India is valued at Rs. 3,600 Cr. growing at 4.6% CAGR Sourc
Slide 19: Life Science Chemicals
Life Science Chemicals Global Market Size (KT): Acetic Global Market Size (KT): Ethyl Anhydride Acetate Global Acetic Anhydride market is 589 KT in FY’20 and is expected to Industry grow at 2.2% to reach 657KT in FY’25 Overview Global Ethyl Acetate market is 2150 KT in FY’20 and is expected to g
Slide 20: Drug Discovery & Development Solutions (Jubilant Biosys)
Drug Discovery & Development Solutions (Jubilant Biosys)
Slide 21: Drug Discovery & Development Solutions
Drug Discovery & Development Solutions Overview Discovery Services up to IND & GMP Drug Discovery Services (Drug Discovery Services) business through Jubilant Biosys Limited provides innovation and collaborative research Full suite of services to our customers including through two research center
Slide 22: Proprietary Novel Drugs (Jubilant Therapeutics)
Proprietary Novel Drugs (Jubilant Therapeutics)
Slide 23: Proprietary Novel Drugs
Proprietary Novel Drugs Innovative Biotech funded and launched as a standalone On value inflection path from preclinical stage to clinical stage US-based entity in 2019 by parent- a global life sciences –two lead programs expected to transition to clinic in 12-18 company months: • Risk diversified p
Slide 24: Proprietary Novel Drugs
Proprietary Novel Drugs Agile and flexible business model to accelerate value creation EXTERNAL VALUE FUNDING UNLOCKING VC / PE Corporate Funding IPO / M&A Strategic investor Parent Company 25-50 Dedicated Scientists PORTFOLIO IN-LICENSING/ OF ASSETS IN OUT-LICENSING/ PARTNERING SUBSIDIARIES PARTNER
Slide 25: Q2'FY21 Results Analysis
Q2’FY21 Results Analysis Ww JUBUANT ‘LIFESCIENCES
Slide 26: JLL – Q2'FY21 Financial Highlights
JLL – Q2’FY21 Financial Highlights Particulars1 Q2'FY20 Q2'FY21 YoY (%) Revenue Revenue at Rs 2,375 Crore, as compared with Rs 2,266 Crore in Pharmaceuticals 1,452 1,516 4% Q2’FY20 Life Science Ingredients 753 784 4% Drug Discovery & Development Solutions 61 75 23% • Pharmaceuticals revenue at Rs
Slide 27: Income Statement – Q2 and H1'FY21
Income Statement – Q2 and H1’FY21 Particulars1 Q2'FY20 Q2'FY21 YoY (%) H1'FY20 H1'FY21 YoY (%) Total Revenue from Operations 2,266 2,375 5% 4,448 4,268 (4%) Pharmaceuticals 1,452 1,516 4% 2,781 2,612 (6%) Life Science Ingredients 753 784 4% 1,559 1,520 (2%) Drug Discovery & Development Solutions 61
Slide 28: FY20 Results Analysis
FY20 Results Analysis Ww JUBUANT ‘LIFESCIENCES
Slide 29: JLL – FY20 Financial Highlights
JLL – FY20 Financial Highlights YoY 1 Particulars FY19 FY20 Change (%) Revenue at Rs 9,154 Crore up from Rs 9,111 Crore in FY19 Revenue • Pharmaceuticals revenue at Rs 5,714 Crore, increased by 7% YoY, Pharmaceuticals 2 5,349 5,714 7% contributing 62% to revenue Life Science Ingredients 3,545 3,17
Slide 30: Adjusted Earnings
Adjusted Earnings Rs Crore Consol EBITDA % Change % Change S. No. Particulars Q4'FY19 Q4'FY20 YoY FY19 FY20 YoY 1 Reported EBITDA 351 556 58% 1,775 1,995 12% 2 One-off Adjustments 37 12 85 72 3 Adjusted EBITDA 388 568 46% 1,860 2,066 11% 4 Reported EBITDA Margin 14.7% 23.3% 19.5% 21.8% 5 Adjusted EB
Slide 31: Income Statement – Q4 & 12M'FY20
Income Statement – Q4 & 12M’FY20 Particulars1 Q4'FY19 Q4'FY20 YoY Growth FY19 FY20 YoY Growth Total Revenue from Operations 2,386 2,391 0% 9111 9,154 0% Pharmaceuticals 1,405 1,483 6% 5349 5,714 7% Life Science Ingredients 912 823 (10%) 3545 3,179 (10%) Drug Discovery & Development Solutions 68 85 2
Slide 32: Debt Profile Q2'FY21
Debt Profile Q2’FY21 Particulars 31-Mar-20 30-Jun-20 30-Sep-20 Foreign Currency Loans (US$ m) (US$ m) (US$ m) Subsidiaries 431 435 435 Total 431 435 435 Rupee Loans (Rs Crore) (Rs Crore) (Rs Crore) Standalone 1,295 985 820 Subsidiaries 100 160 125 Total 1,395 1,145 945 Gross Debt (Rs Crore) (Rs Cror
Slide 33: Demonstrated Financial Track Record with Strong Revenue Growth and Attractive Profitability Profile
Demonstrated Financial Track Record with Strong Revenue Growth and 7 Attractive Profitability Profile Revenue from Operations1 Total Revenue EBITDA Split1 Reported EBITDA2 Revenue increased at a CAGR of 9.5% over FY15-20 and EBITDA 5,826 5,893 5,861 7,518 9,111 9,154 732 1,291 1,370 1,558 1,775 1,
Slide 34: Update on Reorganization Proposal
Update on Reorganization Proposal Post the board approval on Oct 25, 2019 for reorganizing the businesses of the Company, in November 2019 the Company had filed with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) the Composite Scheme of Arrangement for amalgamation of certain P
Slide 35: For more information
For more information For Investors: Hemant Bakhru | Pavleen Taneja Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002| 21 Ph: +91 22 6645 1209 E-mail: hemant.bakhru@jubl.com E-mail: siddharth@cdr-india.com pavleen.taneja@jubl.com For Media: Sudhakar Safaya Clayton Dsou
Jubilant Life Sciences — Investor Presentation (November 2020) on 6ix